Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CTP2D6 genotypes

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 4, 1998, Pages 384-390

  Yue, Qun Ying ^a   Zhong, Zhi Hui ^a   Tybring, Gunnel ^a   Dalén, Per ^a   Dahl, Marja Liisa ^a   Bertilsson, Leif ^a   Sjöqvist, Folke ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

10 HYDROXYNORTRIPTYLINE; CYTOCHROME P450; DEBRISOQUINE; DRUG METABOLITE; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CHINESE; CLINICAL ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG METABOLISM; ETHNIC GROUP; FEMALE; GENOTYPE; HUMAN; MALE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 CYP2D6; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENOTYPE; HUMANS; HYDROXYLATION; MALE; MIDDLE AGED; NORTRIPTYLINE; POLYMERASE CHAIN REACTION; SWEDEN;

EID: 0031668683     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90069-8     Document Type: Article

References (35)

1. Hammer W, Sjöqvist F. Plasma levels of monomethylated tricyclic antidepressants during treatment with imipramine-like compounds. Life Sci 1967;6:1895-903.
2. Alexanderson B, Evans DAP, Sjöqvist F. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. BMJ 1969;2:764-8.
3. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980;27:1673-7.
4. Mellström B, Bertilsson L, Säwe J, Schulz HU, Sjöqvist F. E- and Z-10-OH-nortriptyline of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981;30:189-93.
5. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 1977;2:584-6.
6. Nordin C, Bertilsson L, Siwers B. Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxy-nortriptyline. Clin Pharmacol Ther 1987;42:10-9.
7. Bertilsson L, Alexanderson B. Stereospecific hydroxylation of nortriptyline in man in relation to interindividual differences in its steady-state plasma level. Eur J Clin Pharmacol 1972;4:201-5.
8. Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants. Emphasis on E-10-hydroxynortriptyline. Clin Pharmacokinet 1995;28:26-40.
9. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990; 39:533-7.
10. Yue QY, Svensson JO, Aim C, Sjöqvist F, Säwe J. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 1989;28:629-37.
11. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin [published erratum appears in Clin Pharmacol Ther 1994;55:648]. Clin Pharmacol Ther 1992;51:388-97.
12. Johansson I, Yue QY, Dahl ML, Heim M, Säwe J, Bertilsson L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-6.
13. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994;46:452-9.
14. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993;53:410-8.
15. Yue QY, Bertilsson L, Dahl-Puustinen ML, Säwe J, Sjöqvist F, Johansson I, et al. Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese [letter] [see comments]. Lancet 1989;2:870.
16. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996;6:193-201.
17. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996;6:441-7.
18. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-63.
19. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994;4:73-81.
20. Lou YQ. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev 1990;22:451-75.
21. Rudorfer MV, Lane EA, Chang WH, Zhang MD, Potter WZ. Desipramine pharmacokinetics in Chinese and Caucasian volunteers. Br J Clin Pharmacol 1984;17:433-40.
22. Lin KM, Poland RE, Smith MW, Strickland TL, Mendoza R. Pharmacokinetics and other related factors affecting psychotropic responses in Asians. Psychopharmacol Bull 1991;27:427-39.
23. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in Caucasians with 0, 1, 2, 3 and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444-52.
24. Lennard MS, Silas JH, Smith AJ, Tucker GT. Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection. J Chromatogr 1977;133:161-6.
25. Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995;5:159-64.
26. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
27. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Nail Acad Sci USA 1993;90:11825-9.
28. Tybring G, Nordin J, Widén J. High performance liquid chromatography-mass spectrometry for the quantification of nortriptyline and 10-hydroxynortriptyline in plasma. J Chromatogr [in press].
29. Bertilsson L, Åberg-Wistedt A, Gustafsson LL, Nordin C. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985;7:478-80.
30. Woolhouse NM, Adjepon-Yamoah KK, Mellström B, Hedman A, Bertilsson L, Sjöqvist F. Nortriptyline and debrisoquine hydroxylations in Ghanaian and Swedish subjects. Clin Pharmacol Ther 1984;36:374-8.
31. Nordin C, Siwers B, Benitez J, Bertilsson L. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients: relationship to the debrisoquine hydroxylation metabolic ratio. Br J Clin Pharmacol 1985;19:832-5.
32. Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology 1996;123:315-9.
33. Alexanderson B, Borgå O. Urinary excretion of nortripty-line and five of its metabolites in man after single and multiple oral doses. Eur J Clin Pharmacol 1973;5:174-80.
34. Lai ML, Wang SL, Lai MD, Lin ET, Tse M, Huang JD. Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1995;58:264-8.
35. Tseng CY, Wang SL, Lai MD, Lai ML, Huang JD. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1996;60:177-82.